KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies

Mutation of oncogene KRAS is common in non-small cell lung cancer (NSCLC), however, its clinical significance is still controversial. Independent studies evaluating its prognostic and predictive value usually drew inconsistent conclusions. Hence, We performed a meta-analysis with 41 relative publica...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Wei, Yang, Yan, Zhu, Hongcheng, Zhang, Youcheng, Zhou, Rongping, Sun, Xinchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884999/
https://www.ncbi.nlm.nih.gov/pubmed/26840022
http://dx.doi.org/10.18632/oncotarget.7080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884999/
https://www.ncbi.nlm.nih.gov/pubmed/26840022
http://dx.doi.org/10.18632/oncotarget.7080

Ejemplares similares